PPN12 PETS, PEOPLE AND DEMAND FOR ETODOLAC IN THE UNITED STATES OF AMERICA
Snyder S, Rutkowski A, Jamieson K Lehigh University, Bethlehem, PA, USA OBJECTIVES: To compare price and demand for pharmaceuticals for human and companion animal markets to provide insight into the relative importance of institutional factors or underlying market demand in determining price and utilization for pharmaceuticals in humans. The large majority of owners of companion animals pay the market price for pharmaceutical therapy. Even when pet insurance exist, insurers can charge the expected cost of providing services. In contrast, access to health care for humans is considered an important policy objective, third party payment is the norm, and insurers are typically not free to adjust for an individual's expected costs. METHODS: Comparative review of human and animal regulatory systems, compilation of public estimates for R&D costs, and estimation of linear demand curves for Etodolac in human and companion animal markets. Prices and quantities for Etodolac are taken from studies conducted for the United States Congress. RESULTS: Regulatory processes for both human and pets are similar, but human development costs are much higher due to the greater cost of clinical trials in humans. Average cost per drug approved are estimated at $800 Million for humans and $40 Million for pets (all prices in 2001 dollars) using similar pricing methodologies. We estimate demand in the human market as: Q = 4.8789 − 0.0173P (Q in millions of monthly prescriptions per year, P in dollars). For animals the demand equation is Q = 0.7688 − 0.0061P (units as for humans). If marginal cost pricing were instituted, elasticity of demand would be −0.016 for humans and −0.037 for pets. CONCLUSION: Even at very low prices, we find evidence of less price responsiveness in human pharmaceutical markets, suggesting that institutional factors increase the demand for pharmaceuticals and this effect is quantitatively important. The majority of Actiq prescriptions may be off-label. Given that the drug is a powerful, habit-forming opioid, these data suggest that the use of this drug should be considered for specific utilization review by insurers. These data also track recent evidence indicating that the use of these drugs has increased rapidly in recent years. Future work should examine whether off-label use of Actiq may be related to patient copay or other benefit design characteristics.
PPN14 OFF-LABEL OPIOID USE IN THE TREATMENT OF CHRONIC PAIN

PPN15 EXAMINING FAMILY PHYSICIANS' ATTITUDES AND WILLINGNESS TO PRESCRIBE LONG-ACTING OPIOIDS TO PATIENTS WITH MODERATE TO SEVERE CHRONIC NONMALIGNANT PAIN
Nwokeji ED, Rascati KL, Brown CM The University of Texas at Austin, Austin, TX, USA OBJECTIVES: To examine family physicians' attitudes and willingness to prescribe long-acting opioids to patients with moderate to severe chronic nonmalignant pain (CNMP).
METHODS:
The ory of Planned Behavior (TPB) was used to examine the underlying constructs (i.e., attitude, social influences, and perceived control) believed to influence physicians' willingness to prescribe long-acting opioids for CNMP. Three focus groups were conducted and a web-based survey was developed, pretested, and e-mailed to 2750 Texas family physicians. A total of 64 Likert-type questions were used to assess the predictors of physicians' willingness to prescribe, and 10 of these items measured physicians' attitudes (summed range = −90 to +90). RESULTS: A total of 267 family physicians completed the questionnaire. The TPB model accounted for 39% (F3222 = 47.4, p < 0.001) of the variance in explaining physicians' willingness to prescribe. Most physicians (N = 179, 66%) indicated that they were willing to prescribe long-acting opioids to their CNMP patients. Physicians unwilling to prescribe long-acting opioids for CNMP had an overall unfavorable attitude (Mean = −7.87, SD = 17.43) compared to willing physicians (Mean = +9.56, SD = 17.42). Unwilling physicians held stronger beliefs that prescribing opioids would lead to patient abuse, addiction and regulatory scrutiny compared to willing physicians. A significant positive relationship was found between previous prescribing of long-acting opioids and attitude (R = 0.46, p < 0.01). Respondents who prescribed long-acting opioids more often were less likely to believe that it would lead to abusive and addictive behaviors, while those who prescribed less often were more likely to believe that it would lead to regulatory scrutiny. CONCLU-SION: The TPB model was a significant predictor of physicians'
